The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2021 | CAR T-cells in myeloma: patients’ perspective
CAR T-cell therapy has emerged as a promising therapy for relapsed and/or refractory patients with multiple myeloma. Ananda Plate, LL.B, MSc, Myeloma Patients Europe, Brussels, Belgium, discusses the challenges associated with this therapy from a patients’ perspective. The time lag between the collection and manufacturing of CAR T-cells remains difficult for patients with progressive disease. Side-effects, access to CAR T-cells, and management of expectations are some of the other hurdles related to CAR T-cell therapy. This interview took place during the 3rd European CAR T-cell Meeting.
Disclosures
Myeloma Patients Europe receives funding from most of the pharmaceutical companies developing myeloma and AL amyloidosis drugs. Ananda Plate has no personal disclosures.
